Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Haemonetics share holder equity from 2010 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Haemonetics Share Holder Equity 2010-2025 | HAE

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Haemonetics share holder equity from 2010 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$227.2B
Boston Scientific (BSX)	$140.7B
Stryker (SYK)	$132.3B
EssilorLuxottica (ESLOY)	$128.4B
Medtronic (MDT)	$105.9B
Lonza Group Ag (LZAGY)	$47.4B
Haleon (HLN)	$46.2B
ResMed (RMD)	$31.3B
Agilent Technologies (A)	$29.2B
GE HealthCare Technologies (GEHC)	$28.6B
Terumo (TRUMY)	$28.2B
Koninklijke Philips (PHG)	$22.2B
Zimmer Biomet Holdings (ZBH)	$19.4B
Insulet (PODD)	$17.3B
Baxter (BAX)	$14.8B
Smith & Nephew SNATS (SNN)	$11.4B
Sunny Optical Technology (SNPTF)	$7.6B
Lantheus Holdings (LNTH)	$6.9B
Bio-Rad Laboratories (BIO)	$6.7B
Demant (WILYY)	$6.6B
Prestige Consumer Healthcare (PBH)	$4B
Shandong Weigao Medical Polymer (SHWGF)	$3.5B
Perrigo (PRGO)	$3.5B
ICU Medical (ICUI)	$3.4B
Envista Holdings (NVST)	$2.6B
GN Store Nord (GNNDY)	$2.2B
LeMaitre Vascular (LMAT)	$1.9B
QuidelOrtho (QDEL)	$1.7B
AtriCure (ATRC)	$1.6B
Kestra Medical Technologies (KMTS)	$1.2B